James Mackin Sells 70,000 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) CEO James Mackin sold 70,000 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $28.95, for a total value of $2,026,500.00. Following the sale, the chief executive officer directly owned 877,275 shares of the company’s stock, valued at approximately $25,397,111.25. This represents a 7.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Artivion Stock Performance

Shares of NYSE AORT opened at $28.16 on Friday. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. The stock has a market capitalization of $1.37 billion, a price-to-earnings ratio of -402.23 and a beta of 1.25. The stock’s fifty day simple moving average is $25.08 and its 200 day simple moving average is $30.14. Artivion, Inc. has a 52-week low of $19.16 and a 52-week high of $48.25.

Artivion (NYSE:AORT) last announced its earnings results on Thursday, August 6th. The company reported $0.13 EPS for the quarter. Artivion had a positive return on equity of 6.07% and a negative net margin of 0.67%.The business had revenue of $125.76 million during the quarter, compared to the consensus estimate of $119.99 million. As a group, sell-side analysts forecast that Artivion, Inc. will post 0.45 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have commented on AORT. Wall Street Zen cut shares of Artivion from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Needham & Company LLC restated a “buy” rating and set a $44.00 price target on shares of Artivion in a report on Monday, July 20th. Canaccord Genuity Group upped their price target on shares of Artivion from $39.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday. Weiss Ratings lowered shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, Stifel Nicolaus set a $45.00 price objective on shares of Artivion in a research note on Monday, June 1st. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.83.

Institutional Investors Weigh In On Artivion

Institutional investors have recently bought and sold shares of the business. Verition Fund Management LLC increased its holdings in shares of Artivion by 1.6% in the 3rd quarter. Verition Fund Management LLC now owns 16,912 shares of the company’s stock valued at $716,000 after purchasing an additional 274 shares during the period. Entropy Technologies LP boosted its holdings in shares of Artivion by 6.0% during the fourth quarter. Entropy Technologies LP now owns 5,504 shares of the company’s stock worth $251,000 after purchasing an additional 310 shares during the period. Rockefeller Capital Management L.P. grew its position in Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock valued at $30,000 after purchasing an additional 399 shares in the last quarter. Arizona State Retirement System grew its position in Artivion by 4.6% during the fourth quarter. Arizona State Retirement System now owns 11,235 shares of the company’s stock valued at $512,000 after purchasing an additional 494 shares in the last quarter. Finally, Amundi increased its stake in Artivion by 7.5% in the 1st quarter. Amundi now owns 7,186 shares of the company’s stock valued at $263,000 after buying an additional 501 shares during the period. 86.37% of the stock is currently owned by institutional investors and hedge funds.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.